The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The effect of splicing factor gene mutations on the outcomes of patients with AML
Jayastu Senapati, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a retrospective study evaluating the impact of splicing factor gene mutations on the outcomes of patients with acute myeloid leukemia (AML). Patients with newly diagnosed AML were stratified based on splicing factor gene mutational status, age, therapy intensity and whether they received venetoclax or not. Splicing gene mutations in isolation did not affect overall survival (OS) or response. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
